AI Analysis
AI-generated analysis. Always verify with the original filing.
Galapagos NV entered a binding Framework Agreement with Gilead Sciences to collaborate on advancing gamgertamig and Ouro Medicines' T cell engager programs for autoimmune diseases, securing 50% of acquisition consideration and enhanced cash flexibility.
Key Takeaways
1Galapagos and Gilead to split Ouro acquisition upfront $1.675B and up to $500M milestones 50/50.
2Galapagos gains licenses to gamgertamig (BCMAxCD3 T cell engager in Phase 1/2 for AIHA/ITP) and preclinical programs.
3OLCA waiver frees $500M cash for independent use, including up to $150M for share buybacks.
4Galapagos funds gamgertamig development pre-registrational studies; costs shared equally thereafter.
5Gilead handles commercialization outside Keymed territories, paying Galapagos 20-23% tiered royalties on net sales.
6Gamgertamig has FDA Fast Track/Orphan Drug Designation for AIHA/ITP, expected registrational studies in 2027.